---
title: "Shared IRF4/HERC2 Variants in Uveal and Cutaneous Melanoma: Bioinformatic Evidence and Prognostic"
id: "medrxiv-16-uveal-and-cutaneous-melanoma-share-a-common-mutation-with-distinct-prognostic"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-16-uveal-and-cutaneous-melanoma-share-a-common-mutation-with-distinct-prognostic"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.07.26359988v1?rss=1"
published_at: "2026-08-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Shared IRF4/HERC2 Variants in Uveal and Cutaneous Melanoma: Bioinformatic Evidence and Prognostic
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-16-uveal-and-cutaneous-melanoma-share-a-common-mutation-with-distinct-prognostic
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.07.26359988v1?rss=1)
- **Published At:** 2026-08-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Background: Uveal melanoma (UM) and cutaneous melanoma (CM) both arise from melanocytic lineage, prompting investigation of shared genetic mechanisms. The study used public databases to search for overlapping variant–disease associations (VDAs) between the two melanoma types. - Data sources and methods: The authors queried the **GWAS Catalog** and **DisGeNET** to identify VDAs linked to UM and CM, validated findings in **Ensembl**, and assessed protein–protein interactions using **STRING**. The work is a bioinformatic analysis of publicly available, de‑identified datasets; no new patient data were collected. - VDA counts: The search returned 109 unique VDAs associated with UM and 880 associated with CM. Only two VDAs were shared between UM and CM across different ethnic groups. - Shared variants: The two shared VDAs are **rs12203592** (in the **IRF4** gene) and **rs12913832** (in the **HERC2** gene). These specific single‑nucleotide variants appeared in associations for both melanoma types in the databases queried. - Protein interactions: STRING network analysis indicated that OCA2 and **IRF4** have direct interactions with **HERC2**, suggesting a molecular connection among these proteins relevant to pigmentation pathways and melanoma biology. - Prognostic implications reported: The authors report that **HERC2** functions as a poor prognostic factor in uveal melanoma, while **IRF4** status is an important prognostic indicator in both UM and CM. The study highlights the potential value of IRF4 allele characterization for understanding pathogenesis and tailoring disease‑specific approaches. - Limitations and context: This is a preprint bioinformatic study using existing database associations; it has not been peer reviewed and should not guide clinical practice. Data and code sources are publicly available from GWAS Catalog, DisGeNET, and Ensembl as listed in the manuscript. - Ethics and data availability: The authors state that analysis used publicly available, de‑identified data and that ethics approval and informed consent were not required. Data availability links are provided for the three databases used.
## Clinical Analysis & Structured Key Points
Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study | medRxiv Skip to main content Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study Fatemeh Razmjooei , View ORCID Profile Hamidreza Ashayeri , Zahra Jafarzadeh , Porya Dabbaghabdollahi , View ORCID Profile Ali Jafarizadeh doi: https://doi.org/10.64898/2026.08.07.26359988 Fatemeh Razmjooei 1 Shiraz University of Medical Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hamidreza Ashayeri 2 Tabriz University of Medical Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Hamidreza Ashayeri Zahra Jafarzadeh 3 Jahrom University of Medical Science Find this author on Google Scholar Find this author on PubMed Search for this author on this site Porya Dabbaghabdollahi 2 Tabriz University of Medical Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ali Jafarizadeh 2 Tabriz University of Medical Sciences; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ali Jafarizadeh For correspondence: jafarizadeha{at}tbzmed.ac.ir Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Uveal melanoma (UM) and cutaneous melanoma (CM) both originate from the same cell line. This proposes the possibility of a shared mechanism between entities, requiring explicit investigation. Methods: Data from GWAS Catalog and DisGeNET were used to identify shared variation-disease associations (VDAs) between UM and CM. The results were validated using the Ensembl database. In the next step, the STRING database was used to identify the protein–protein interaction. Results: Subsequently, 109 unique VDAs were identified for UM and 880 for CM. However, only 2 VDAs were found to be shared among UM and CM in different ethnic groups. These shared VDAs were rs12203592 of the IRF4 gene, rs12913832 of the HECT and RLD domain-containing E3 ubiquitin protein ligase 2 (HERC2) gene. Notably, PPI network assessment through STRING showcased that OCA2 and IRF4 directly interacted with HERC2. Conclusion: While HERC2 acts as a poor prognostic factor in uveal melanoma, IRF4 status is a key prognostic indicator in both UM and CM. Identifying IRF4 allele contributions enables a better understanding of melanoma pathogenesis and fosters the development of disease-specific approaches. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was conducted using publicly available, de-identified data from established databases (GWAS Catalog, DisGeNET, and Ensembl) and did not involve human participants or identifiable personal data. Therefore, ethics approval and informed consent were not required. The Declaration of Helsinki was strictly followed during the course of this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data that support the findings of this study are openly available in GWAS Catalog (at https://www.ebi.ac.uk/gwas/), DisGeNET (at https://disgenet.com/), and Ensembl (at https://www.ensembl.org/index.html). https://www.ensembl.org/index.html https://disgenet.com/ https://www.ebi.ac.uk/gwas/ Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted August 11, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study Fatemeh Razmjooei , Hamidreza Ashayeri , Zahra Jafarzadeh , Porya Dabbaghabdollahi , Ali Jafarizadeh medRxiv 2026.08.07.26359988; doi: https://doi.org/10.64898/2026.08.07.26359988 Share This Article: Copy Citation Tools Uveal and cutaneous melanoma share a common mutation with distinct prognostic implications: A bioinformatic study Fatemeh Razmjooei , Hamidreza Ashayeri , Zahra Jafarzadeh , Porya Dabbaghabdollahi , Ali Jafarizadeh medRxiv 2026.08.07.26359988; doi: https://doi.org/10.64898/2026.08.07.26359988 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (601) Allergy and Immunology (891) Anesthesia (322) Cardiovascular Medicine (4708) Dentistry and Oral Medicine (467) Dermatology (403) Emergency Medicine (632) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1599) Epidemiology (15701) Forensic Medicine (32) Gastroenterology (1185) Genetic and Genomic Medicine (6904) Geriatric Medicine (722) Health Economics (1040) Health Informatics (4891) Health Policy (1415) Health Systems and Quality Improvement (1712) Hematology (570) HIV/AIDS (1314) Infectious Diseases (except HIV/AIDS) (16175) Intensive Care and Critical Care Medicine (1151) Medical Education (653) Medical Ethics (150) Nephrology (710) Neurology (7078) Nursing (358) Nutrition (1062) Obstetrics and Gynecology (1212) Occupational and Environmental Health (989) Oncology (3530) Ophthalmology (1018) Orthopedics (383) Otolaryngology (436) Pain Medicine (460) Palliative Medicine (136) Pathology (696) Pediatrics (1757) Pharmacology and Therapeutics (726) Primary Care Research (753) Psychiatry and Clinical Psychology (5757) Public and Global Health (9584) Radiology and Imaging (2342) Rehabilitation Medicine and Physical Therapy (1412) Respiratory Medicine (1231) Rheumatology (629) Sexual and Reproductive Health (759) Sports Medicine (569) Surgery (753) Toxicology (105) Transplantation (300) Urology (280)
## Related Clinical Research

- [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)
- [FDA approves first targeted pancreatic cancer drug; Trump administration strikes biotech drug-pric](https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump.md)
- [Moderna–Merck cancer vaccine and the role of the algorithm behind its mRNA design](https://medichelpline.com/clinical-feed/stat-news-1-stat-the-mystery-of-moderna-s-magic-algorithm.md)
- [State Tanning Bed Availability Linked to Higher Early-Onset Melanoma in Midwest and South](https://medichelpline.com/clinical-feed/medrxiv-1-state-tanning-bed-availability-is-associated-with-early-onset-melanoma.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.